Reference

Ezetimibe

Ezetimibe. Meyer zu Schwabedissen, H.; Kroemer, H.Some commonly used reagents like 57-88-5 and 163222-33-1 are used in this experiment. K. (Abteilung fuer Allgemeine Pharmakologie, Institut fuer Pharmakologie und Toxikologie, Ernst-Moritz-Arndt Universitaet, Greifswald, Germany). Deutsche Medizinische Wochenschrift, 129(39), 2038-2040 (German) 2004 Georg Thieme Verlag. CODEN: DMWOAX. ISSN: 0012-0472. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review on properties and pharmacokinetics, mechanism of action, indications, and side effects of ezetimibe, a selective cholesterol absorption inhibitor ezetimibe. Efficacy and safety are discussed of ezetimibe coadministration with statins in lipid lowering therapy. .

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.Some chemicals with cas registry numbers like 49562-28-9 and 163222-33-1 are also used. Kosoglou, Teddy; Statkevich, Paul; Fruchart, Jean-Charles; Pember, Laura J. C.; Reyderman, Larisa; Cutler, David L.; Guillaume, Michel; Maxwell, Stephen E.; Veltri, Enrico P. (Department of Early Clinical Research and Experimental Medicine, Schering-Plough Research Institute, Kenilworth, NJ, USA). Current Medical Research and Opinion, 20(8), 1197-1207 (English) 2004 LibraPharm Ltd. CODEN: CMROCX. ISSN: 0300-7995. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The cholesterol absorption inhibitor, ezetimibe, significantly decreases low-d. lipoprotein-cholesterol (LDL-C) levels in patients with primary hypercholesterolemia. The pharmacodynamic, pharmacokinetic, and safety profiles of ezetimibe and fenofibrate were evaluated alone and after co-administration in 32 subjects with primary hypercholesterolemia. This was a randomized, evaluator (single)-blind, placebo-controlled, parallel-group study. Subjects with untreated LDL-C 3 130 mg/dL (3.37 mmol/L) were randomized to receive one of four oral treatments each morning for 14 days: fenofibrate 200 mg + ezetimibe 10 mg, fenofibrate 200 mg, ezetimibe 10 mg, or placebo. Serum lipids were assessed before drug administration on day 1, day 7, and day 14. Pharmacokinetic parameters were assessed on day 14. The primary pharmacodynamic parameter was percentage change from baseline in LDL-C concn. following co-administration of ezetimibe and fenofibrate vs. either drug alone, or placebo. A secondary outcome was the potential for a pharmacokinetic interaction between ezetimibe and fenofibrate. Ezetimibe and fenofibrate co-administration was well tolerated and produced statistically significant mean percentage redns. from baseline in LDL-C (p ￡ 0.05 vs. either drug alone or placebo), total cholesterol and triglycerides (p ￡ 0.05 vs. either fenofibrate or placebo), apolipoprotein C-III (p ￡ 0.05 vs. placebo), and LDL-III (p ￡ 0.05 vs. either drug alone or placebo). Ezetimibe did not significantly affect the pharmacokinetics of fenofibrate. Concomitant fenofibrate administration significantly increased the mean Cmax and AUC of total ezetimibe approx. 64% and 48%, resp. However, based on the established safety profile and flat dose-response of ezetimibe, this effect is not considered to be clin. significant. Co-administration of ezetimibe and fenofibrate produced significantly greater redns. in LDL-C than either drug alone and greater redns. in triglycerides than fenofibrate. These effects were accompanied by improvements in the lipid/lipoprotein profile, suggesting that co-administration therapy with ezetimibe and fenofibrate may be an effective therapeutic option for patients with mixed dyslipidemia. .